Bodemer C, Kaszuba A, Kingo K, et al. - Researchers conducted this multicentre, double‐blind study to test the safety and effectiveness of two secukinumab dosing regimens (low dose [LD] and high dose [HD]) in paediatric patients with severe chronic plaque psoriasis over one year. Patients aged 6 to < 18 years with severe chronic plaque psoriasis were stratified and randomized by weight (< 25 kg, 25 to <50 kg, ≥ 50 kg) and age (6 to < 12 years, 12 to < 18 years) to obtain low‐dose (LD: 75/75/150 mg) or high‐dose (HD: 75/150/300 mg) subcutaneous secukinumab or placebo or etanercept 0.8 mg/kg (up to a max of 50 mg). A total of 162 patients were randomized to obtain secukinumab LD (n = 40) or HD (n = 40), etanercept (n = 41) or placebo (n = 41). In paediatric patients with severe chronic plaque psoriasis, both doses of secukinumab showed high and sustained efficacy up to Week 52 with a favourable safety profile.